Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1997 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (8507)	12/17/1997 3:51:00 AM
From: Bill Wexler	Read Replies (1) \| Respond to of 9285

Understanding ED...and why ZONA is a complete scam: uspharmacist.com It's interesting to note that Zonagen relied on deceiving naive investors by obfuscating the fact that the active ingredients in its ED solution is not proprietary. Both Vivus and Zonagen are trying to sell new delivery systems. In Vivus's case, the company also benefited from the fact that the FDA approved alprostadil for the treatment of ED. Zonagen - of course - is relying on the oral delivery of phentolamine - which is ineffective. It is easy to see why Zonagen has been playing smoke and mirrors with the Phase II and III results.